Drug Profile
Synthetic ghrelin - Oxeia Biopharmaceuticals
Alternative Names: OXE-103; SUN-11031Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Kyoto University
- Developer Asubio Pharma; KineMed; Oxeia Biopharmaceuticals
- Class Peptide hormones; Radioprotectives; Vascular disorder therapies
- Mechanism of Action Ghrelin replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Brain injuries
- Discontinued Anorexia nervosa; Cachexia; Muscular atrophy